Parexel has expanded its early phase drug development capabilities with a dedicated unit to provide biopharmaceutical companies with support for proof-of-concept studies. The new unit integrates capabilities in regulatory strategies, drug development, and clinical pharmacology. Proof-of-concept studies are mainly used in targeted patient populations and are designed to demonstrate early signals of a product’s efficacy. The goal of these studies is to help avoid costly late stage clinical d...